Expression of CD30 in patients with acute graft-versus-host disease - Wikidata - wikimedia - TriplyDB

Expression of CD30 in patients with acute graft-versus-host disease

Expression of CD30 in patients with acute graft-versus-host disease

http://www.wikidata.org/entity/Q41984840

about

Graft-versus-host disease biomarkers: omics and personalized medicine Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Increased bone marrow (BM) plasma level of soluble CD30 and correlations with BM plasma level of interferon (IFN)-γ, CD4/CD8 T-cell ratio and disease severity in aplastic anemia Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Emerging drugs for graft-versus-host disease.Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation.Increased plasmacytoid dendritic cells and RORγt-expressing immune effectors in cutaneous acute graft-versus-host disease.New and emerging therapies for acute and chronic graft versus host disease.Differential expression of CD30 on CD3 T lymphocytes in patients with systemic lupus erythematosus.Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD.Elevated bone marrow eosinophil count is associated with high incidence of severe acute GvHD after allogeneic hematopoietic stem cell transplantation.

P2860

Q26824540-79BE71DA-BC45-477F-B4BB-5F51AC056210 Q33420273-272AD177-37F3-48A7-A763-0763C6531155 Q34482699-7446C538-9EEB-413B-9803-28B61A7A8D94 Q35180727-2E86247C-33EF-40CF-927D-17A8211ADA1B Q38664909-C2417C9B-0010-4969-A237-3F6CF2AA6CF6 Q38786084-72D5D51E-A895-48AA-9964-A92F93B69262 Q42241622-C93194DA-0832-4C62-94BC-8FB92CC24E31 Q44966896-6BD0320E-A54D-4B62-B47A-A4E3FBB78FC5 Q49238507-61FD358A-B74C-4A3E-AB67-83CC3228E96F Q50888578-33C12393-7359-4AB7-8D37-0899F4BB1196 Q50934101-BA6726CC-9B2D-40A4-8B1B-D7D190EE136D Q53211927-2557F935-C819-402C-8002-D6EFB25C3F7B

P2860

Expression of CD30 in patients with acute graft-versus-host disease

http://www.wikidata.org/entity/Q41984840

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Expression of CD30 in patients with acute graft-versus-host disease

@en

type

label

Expression of CD30 in patients with acute graft-versus-host disease

@en

prefLabel

Expression of CD30 in patients with acute graft-versus-host disease

@en

P1433

Q41984840-275660E2-CB6D-44F9-B431-22D0E1DAD89B

P1476

Q41984840-3526A641-814A-42AC-B22D-128317595C5F

P2093

Q41984840-00FBE298-E300-44C4-8092-95D1C97E3E8C

Q41984840-333F4B20-C46B-4039-9198-E7142E4DCBE7

Q41984840-5B49C75B-C7AB-4012-92F2-75F1462E90B0

Q41984840-6FDC7D39-A318-4756-90FA-3AA2CB823DC3

Q41984840-7B13659D-FF1E-47D0-AAF8-6C7E6507E383

Q41984840-A2497945-2CC0-4F84-A3B1-524CA4B4CB26

Q41984840-A5EC6B86-2241-4732-8798-90467C6EB3C1

Q41984840-BAC5D5A4-7469-4418-B217-59C0012D1B3F

Q41984840-D6641AA4-2745-4067-B568-D3700E5EF3A0

Q41984840-F33FEAA7-708F-44C6-BFDD-4C36BDC8C6C8

P2860

Q41984840-07C328A1-AFD3-424D-90C4-C1E9FF95420B

Q41984840-32DFFA1B-07FC-4FA4-BB92-1476A505E3C8

Q41984840-6E039FC8-5299-40AC-A603-699B4E09CD55

Q41984840-72C28392-F2D3-4248-B401-88271ACAE420

Q41984840-735EA699-B5AE-4D06-985C-BB58660B3968

Q41984840-74078D33-24C6-40F2-8AF9-F7C35A04DDFD

Q41984840-8F55B5B0-88DD-40A6-88E6-6CF1CDFAEEB3

Q41984840-A6CC0A02-5757-4C0D-A3F2-1A58746D92E6

Q41984840-BEC42FA4-6B5C-42D6-8BE4-686D900469E0

Q41984840-D00F78B6-E957-4E43-8239-D546F03A2B47

P304

Q41984840-CF90B797-C2FA-4463-867D-E49108FB7A6B

P31

Q41984840-8087A0C4-ABD2-4739-83AB-546A31E0D17F

P356

Q41984840-94AC7F64-F5F8-4198-BA4C-2A2F04C4DED5

P407

Q41984840-0D0EDEF7-9893-40A7-B664-2D78A94A6D50

P433

Q41984840-FFD9224E-1E27-41DB-A2D5-41A8DA82A764

P478

Q41984840-11F470A9-5F83-4C6F-B568-0EED3042F656

P50

Q41984840-FB63DCE3-5E13-4898-9106-C521D2DBE558

P577

Q41984840-2645D7EC-E5CE-4D13-822D-978FEE60F7E1

P5875

Q41984840-89FC1E96-AD12-40A7-B298-69C8176E3E0D

P698

Q41984840-136AF165-13C0-4183-9DAC-722CBE45C6EA

P932

Q41984840-4A3A4777-A022-44A0-A7DB-A9BE5827AA26

P356

BLOOD-2012-03-415422

P1433

P1476

Expression of CD30 in patients with acute graft-versus-host disease

@en

P2093

Christina Illiano

http://www.w3.org/2001/XMLSchema#string

Corey S Cutler

http://www.w3.org/2001/XMLSchema#string

Erin Coughlin

http://www.w3.org/2001/XMLSchema#string

Heidi Chen

http://www.w3.org/2001/XMLSchema#string

In Sun Park

http://www.w3.org/2001/XMLSchema#string

Madan Jagasia

http://www.w3.org/2001/XMLSchema#string

Robert Hasserjian

http://www.w3.org/2001/XMLSchema#string

Robert J Soiffer

http://www.w3.org/2001/XMLSchema#string

Sean McDonough

http://www.w3.org/2001/XMLSchema#string

Thomas R Spitzer

http://www.w3.org/2001/XMLSchema#string

P2860

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.

Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.

CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses.

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment.

Sirolimus for treatment of steroid-refractory acute graft-versus-host disease.

Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy.

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.

P304

691-696

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-03-415422

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225095775

http://www.w3.org/2001/XMLSchema#string

P698

22661699

http://www.w3.org/2001/XMLSchema#string

P932

3401221

http://www.w3.org/2001/XMLSchema#string